8-K: Carisma Therapeutics Announces Promising Preliminary Data from CT-0508 Cancer Trials

Carisma Therapeutics reported encouraging preliminary results from its Phase 1 clinical trial of CT-0508, both as a monotherapy and in combination with pembrolizumab, for treating HER2 overexpressing cancers.

Summary

• Carisma Therapeutics shared preliminary data from its Phase 1 clinical trial of CT-0508, a therapy targeting HER2 overexpressing cancers.
• In the monotherapy trial, 40.7% of target lesions across all anatomic sites showed a reduction in size in at least one scan across 14 patients.
• The company also presented data from a sub-study combining CT-0508 with pembrolizumab, involving six patients, with initial data from the first three patients.
• The combination therapy was generally well-tolerated with no dose-limiting toxicities reported in the first three patients.
• The first two patients in the combination study received corticosteroids after CT-0508 infusion and prior to pembrolizumab, which may have impacted the results.
• The first two patients in the combination study showed progressive disease, while the third patient showed stable disease.
• The third patient in the combination study, despite high baseline T-cell exhaustion, showed a 46% reduction in one of two target lesions and the greatest increase in peripheral blood T cell clonality seen to date across all seventeen patients treated with CT-0508.

Sentiment

Score: 6

Explanation: The document presents mixed results with some positive signals, but also some concerns about the impact of corticosteroids and the limited number of patients in the study. The monotherapy results are encouraging, but the combination therapy results are less clear.

Positives

• The monotherapy trial showed a 40.7% reduction in target lesion size across all anatomic sites.
• The combination therapy was well-tolerated with no dose-limiting toxicities.
• One patient in the combination study achieved stable disease and a 46% reduction in one of two target lesions.
• The third patient in the combination study showed a significant increase in T cell clonality.

Negatives

• The first two patients in the combination study showed progressive disease.
• Corticosteroids, used in the first two combination patients, may have reversed the activity of CT-0508.
• The results are preliminary and limited.

Risks

• The use of corticosteroids may negatively impact the effectiveness of CT-0508.
• The data is preliminary and based on a small number of patients.
• The combination therapy results are mixed, with some patients showing progressive disease.

Future Outlook

The company will continue to monitor and assess the data from the ongoing clinical trials.

Management Comments

• The company believes that systemic corticosteroids have the potential to reverse the activity of CT-0508.
• The company observed a best overall response of progressive disease in the first two patients and stable disease in the third patient per RECIST 1.1 criteria.

Industry Context

The results are relevant to the field of cancer immunotherapy, particularly in the development of CAR-T cell therapies and macrophage-based therapies. The combination with pembrolizumab, an immune checkpoint inhibitor, is a common strategy in cancer treatment.

Comparison to Industry Standards

• The 40.7% reduction in target lesions in the monotherapy trial is a promising result compared to some other early-stage cancer therapies.
• The combination therapy results are mixed, with some patients showing progressive disease, which is not uncommon in early-stage trials of combination therapies.
• The case study of patient 3, showing a 46% reduction in one lesion and increased T-cell clonality, is a positive signal, especially given the patient's prior treatment history and resistance to other therapies such as Enhertu.
• Pembrolizumab monotherapy in esophageal cancer has shown limited efficacy with an ORR of 5% and PFS of 1.5 months, making the 3.25 month PFS in patient 3 potentially significant.

Stakeholder Impact

• Shareholders may react positively to the promising monotherapy results but may be concerned about the mixed results of the combination therapy.
• Patients with HER2 overexpressing cancers may see this as a potential new treatment option.
• The medical community will be interested in the data and the potential of macrophage-based therapies.

Next Steps

• The company will continue to monitor and assess the data from the ongoing clinical trials.
• Further investigation into the impact of corticosteroids on CT-0508 activity is warranted.

Key Dates

Keywords

CT-0508, HER2, Cancer Therapy, Pembrolizumab, Clinical Trial, Monotherapy, Combination Therapy, Immunotherapy, Oncology, Macrophage